171 articles with Recipharm AB
Net sales increased 10 per cent compared to Q2 2018, corresponding to the net of acquisitions and discontinuing operations.
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
At the Annual General Meeting in Recipharm AB on May 13, 2019, the shareholders adopted the resolutions summarized
Recipharm launches Recipharm Inhalation SolutionsTM as its end-to-end offering for inhalation products
Recipharm, the contract development and manufacturing organisation, has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
With revenue increase of 20 per cent in the first quarter we report all-time high net sales, first time over SEK 1.8 billion in a quarter.
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
The report summarises the business and highlights for 2018 and gives insights into the company’s strategy.
The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019.
The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.
Recipharm has announced that its 2018 International Environmental Award will be presented to Dr. Bryan Brooks, Distinguished Professor in Environmental Science and Biomedical Studies at Baylor University in Waco, Texas.
The Nomination Committee has consisted of Axel Calissendorff, Chairman of the nomination committee, Lars Backsell, Johan Lannebo and Ossian Ekdahl.
Recipharm, the contract development and manufacturing organisation, has achieved the new ISO 45001 certification at its Wasserburg facility in Germany.
Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom
Recipharm will publish its full year report for January – December 2018 on 21 February at 7:45 am CET.
Recipharm announced that all fifteen of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe ahead of the February 9th deadline.
Recipharm, the contract development and manufacturing organisation, has appointed a new director of business management for the USA and Canada to accelerate growth in the region.
Recipharm today announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.
OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.
Recipharm has announced that its proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease).
Thomas Eldered, CEO and co-founder of Recipharm AB, has informed the Company that he has sold 1,559,125 Class B shares in Recipharm, representing approximately 12.7% of his total shareholding in the Company, to a Swedish institutional investor.